Table 1.
Selection of clinical trials and approved antiangiogenic therapies in hematological malignancies
| Drug | Target | Study entities | Approved for |
|---|---|---|---|
| Receptor tyrosine kinase inhibitors | |||
| PTK787/ZK 222584 (Vatalanib®) | VEGFR1-3, PDGFRb, c-Kit | AML, PMF, MDS, CML, DLBCL, MM | |
| SU5416 (Semaxinib) | VEGFR1-2, c-kit, Flt3 | AML, MDS, MM, MPN | |
| Sorafenib (Nexavar®) | VEGFR2-3, B-Raf, Faf-1, PDGFRb | AML, ALL, MDS, CML, CLL, NHL, MM | Advanced renal cell carcinoma, HCC |
| Sunitinib (Sutent®) | VEGFR1-3, PDGFRα + b, c-kit, Flt3 | AML, MDS, CLL, myeloma, NHL | Advanced renal cell carcinoma, GIST |
| PKC-412 (Midostaurin) | VEGFR2, PKC, PDGFR, Flt3, c-Kit | AML | |
| Cediranib (Recentin®) | VEGFR1-3, PDGFRb, c-Kit | AML, MDS, CLL | |
| Proteasome inhibitors | |||
| Bortezomib (Velcade®) | 26S proteasome, NF-κB | AML, ALL, MDS, CML, NHL, MCL | MM, MCL |
| Anti-VEGF strategies | |||
| Bevacizumab (Avastin®) | VEGF-A | AML, MDS, CLL, CML, NHL, MM | Metastatic colorectal cancer, NSCLC, breast cancer |
| Immunomodulatory drugs | |||
| Thalidomide | bFGF, VEGF, IL-6 | AML, MDS, MPN, CLL, NHL, MM | MM |
| Lenalidomide (Revlimid®) | bFGF, VEGF, IL-6 | AML, MDS, CLL, NHL | MM, 5q-MDS |
AML acute myeloid leukemia, bFGF basic fibroblast growth factor, DLBCL diffuse large B-cell lymphoma, CLL chronic lymphocytic leukemia, CML chronic myeloid leukemia, GIST gastrointestinal stromal tumors, HCC hepatocellular carcinoma, IL-6 interleukin-6, NHL non-Hodgkin lymphoma, NSCLC non-small-cell lung cancer, MCL mantle cell lymphoma; MDS myelodysplastic syndrome, MM multiple myeloma, MPN myeloproliferative neoplasm, PMF primary myelofibrosis, VEGF vascular endothelial growth factor, PDGFR platelet-derived growth factor receptor